comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-01 23:58:35 - browse：4172

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Listen: Biogen's potential pivot, & Illumina's next chapter

leisure time

WSS

'Make People Better': The CRISPR babies story you probably don't know

NIH nominee Bertagnolli will get October confirmation hearing

Humana sues Biden admin over Medicare Advantage audit rule

FDA authorizes Novavax’s updated Covid

Bristol 'take

Chemotherapy drug shortage eases slightly but still widespread

explore

comprehensive

Wikipedia

23andMe had bad news about my health. I wish a person had delivered it

Was Amgen transparent enough on FDA's concern on cancer drug?

In Memoriam: Notable people who died in 2023

Phenylephrine and the overlooked value of the placebo effect

Psychedelics group wrestles with new pharma identity

Illumina names Agilent executive as new CEO

As demand for Covid shots wanes, Moderna seeks its next success

Covid hospitalizations on the rise, Humana says

The cancer drug shortage isn’t new — and neither are the solutions

What drug price negotiations mean for Medicare Part D

Wikipedia

What American doctors can learn from their Israeli counterparts

Phenylephrine and the overlooked value of the placebo effect

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Colorectal cancer study finds potential in overlooked immune cell

Snackable artificial intelligence, expert AI, and the pharma industry

Chemotherapy drug shortage eases slightly but still widespread

Wikipedia

hotspot

leisure time

focus